PER® New York GU

Wenxin (Vincent) Xu, MD, discusses the factors he takes into account when sequencing treatment options for patients with metastatic renal cell carcinoma.

Peter A. Humphrey, MD, PhD, presents on the standing of artificial intelligence in prostate cancer pathology.

The inter-tumoral complexity of metastatic castration-resistant prostate cancer poses a treatment challenge that may be tackled by examining clonal evolution.

Scott T. Tagawa, MD, MS, FACP, FASCO, discusses the standing of PARP inhibitors in the treatment paradigm of metastatic castration-resistant prostate cancer.

Robert Dreicer, MD, discusses the shortcomings of current clinical trials in prostate cancer and what he sees as the biggest area of improvement.

The burst of translational research leading to PARP inhibitors in prostate cancer, along with imaging and diagnostic advances, has been a monumental evolution for the management of this disease.

Although the immune system plays a vital role in attacking tumor cells, the immune mechanisms vary from tumor to tumor, and factors in the tumor microenvironment can reduce the effectiveness of the body’s immune response.

Despite a perhaps overwhelming number of combination regimens available for use in the frontline setting for patients with renal cell carcinoma, treatment decisions can still largely boil down to a patient’s risk status. For second-line therapy, investigators are looking to contemporary trials for guidance.

Patients with metastatic castration-resistant prostate cancer have traditionally been burdened by a poor outlook; however, emerging therapeutic targets and novel agents directed at them are poised to affect change in this population.

The history of radiation therapy for men with prostate cancer extends back more than a century. From those early crude methods, the field has advanced to delivery potentially curative therapies that can be administered in as little as 2 weeks.